EUVIMEDEUVIMED entdecken
Crossref

Clinical characteristics, treatment and prognosis of nivolumab induced cytokine release syndrome

Shaoli Zhao, Wei Sun, Liping Peng, Chunjiang Wang

Supportive Care in Cancer · 2026-10 · 34 (10)

DOI: 10.1007/s00520-026-11303-8 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Supportive Care in Cancer, online erschienen am 30.09.2026. Verfasst von Shaoli Zhao und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Endocrinology, The Third Xiangya Hospital, Central South University, Changsha, 410013, Hunan, China. Hauptthemen laut MEDLINE: Nivolumab, Cytokine Release Syndrome, Antineoplastic Agents, Immunological. Die Arbeit nennt 27 Literaturangaben. Gefördert von: Hunan Provincial Key Laboratory of the Traditional Chinese Medicine Agricultural Biogenomi.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: To explore the clinical patterns of nivolumab-induced cytokine release syndrome (CRS), and to provide a basis for diagnosis, treatment and prognosis. METHODS: Clinical reports of nivolumab-induced CRS before March 31, 2026 were collected, and clinical data were extracted for retrospective analysis. RESULTS: Thirty-five patients were included, with a median age of 55 years (range 3, 86). The median time for the appearance of CRS was 54.5 days (range 0.2, 391) and the median number of cycles was 3 (range 1, 17). Fever (85.7%), hypotension (57.1%), tachycardia (42.9%), fatigue (25.7%), rash (25.7%) and impaired consciousness (25.7%) were the main symptoms of patients. Laboratory tests may reveal liver injury, renal injury, elevated C-reactive protein, elevated ferritin, and elevated interleukin-6. After discontinuing nivolumab and receiving treatment with glucocorticoids and tocilizumab, 71.4% of the patients showed improvement in symptoms and clinical markers, while 28.6% of the patients died. CONCLUSION: Nivolumab-induced CRS can lead to multi-organ functional impairment and even be fatal. During the administration of nivolumab, the possibility of CRS should be taken into consideration. Glucocorticoids and tocilizumab are widely utilized as primary therapeutic approaches for the management of CRS in clinical practice. However, given the limited available evidence and inherent clinical confounders, the standardized and optimal treatment strategy for nivolumab-induced CRS remains undefined and requires further exploration.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

NivolumabCytokine Release SyndromeAntineoplastic Agents, ImmunologicalHumansFemaleRetrospective StudiesPrognosisMaleAgedMiddle AgedAntibodies, Monoclonal, HumanizedAdultAged, 80 and overAdolescentChildChild, PreschoolYoung AdultGlucocorticoidsNeoplasms

Stichwörter der Autor:innen

Cytokine release syndromeImmune checkpoint inhibitorsImmune-related adverse eventsNivolumabTocilizumab

Substanzen

NivolumabAntineoplastic Agents, ImmunologicalAntibodies, Monoclonal, HumanizedtocilizumabGlucocorticoids

Autor:innen und Institutionen

  • Department of Endocrinology, The Third Xiangya Hospital, Central South University, Changsha, 410013, Hunan, China.
  • Department of Pharmacy, The Third Xiangya Hospital, Central South University, No. 138 Tongzipo Road, YueLu District, Changsha, 410013, Hunan, China.
  • Department of Cardiology, The Third Xiangya Hospital, Central South University, Changsha, 410013, Hunan, China.
  • Department of Pharmacy, The Third Xiangya Hospital, Central South University, No. 138 Tongzipo Road, YueLu District, Changsha, 410013, Hunan, China. wongcj@csu.edu.cn.
  • College of Pharmacy, Changsha Medical University, Changsha, 410219, Hunan, China. wongcj@csu.edu.cn.
  • Hunan Provincial Key Laboratory of the Research and Development of Novel Pharmaceutical Preparations, Changsha Medical University, Changsha, 410219, Hunan, China. wongcj@csu.edu.cn.

Förderung

  • Hunan Provincial Key Laboratory of the Traditional Chinese Medicine Agricultural Biogenomi

Zitieren

APA

Zhao, S., Sun, W., Peng, L., & Wang, C. (2026). Clinical characteristics, treatment and prognosis of nivolumab induced cytokine release syndrome. Supportive Care in Cancer, 34(10). https://doi.org/10.1007/s00520-026-11303-8

Vancouver

Zhao S, Sun W, Peng L, Wang C. Clinical characteristics, treatment and prognosis of nivolumab induced cytokine release syndrome. Supportive Care in Cancer. 2026;34(10). doi:10.1007/s00520-026-11303-8

BibTeX
@article{Zhao2026,
  author = {Zhao, Shaoli and Sun, Wei and Peng, Liping and Wang, Chunjiang},
  title = {Clinical characteristics, treatment and prognosis of nivolumab induced cytokine release syndrome},
  journal = {Supportive Care in Cancer},
  year = {2026},
  volume = {34},
  number = {10},
  doi = {10.1007/s00520-026-11303-8}
}
Kostenlos starten →